4.1 Orientaciones normativas de la OMS sobre los métodos de diagnóstico de la TB y el fortalecimiento de laboratorios
Systematic screening for active TB: principles and recommendations. WHO/HTM/TB/2013.04. Ginebra: Organización Mundial de la Salud. 2013. https://www.who.int/tb/tbscreening/en/.
Xpert MTB/RIF assay for the diagnosis of pulmonary and extrapulmonary TB in adults and children. Policy update. WHO/HTM/TB/2013.16. Ginebra: Organización Mundial de la Salud. 2013.http://www.who.int/tb/publications/xpert-mtb-rif-assay-diagnosis-policy-update/en/
The End TB Strategy – global strategy and targets for TB prevention, care and control after 2015. Ginebra: Organización Mundial de la Salud. 2014. http://www.who.int/tb/strategy/End_TB_Strategy.pdf.
Policy framework for implementing new TB diagnostics. WHO/HTM/TB/2015.11. Ginebra: Organización Mundial de la Salud. 2015. http://www.who.int/tb/publications/implementing_TB_diagnostics/en/.
Chest radiography in TB detection. Summary of current WHO recommendations and guidance on programmatic approaches. Ginebra: Organización Mundial de la Salud. 2016. https://www.who.int/tb/publications/chest-radiography/en/.
Framework of indicators and targets for laboratory strengthening under the End TB Strategy. WHO/HTM/TB/2016.18. Ginebra: Organización Mundial de la Salud. 2016. http://www.who.int/tb/publications/labindicators/en/.
Frequently asked questions about the implementation of the new WHO recommendation on the use of the shorter MDR-TB regimen under programmatic conditions, Versión: 20 de diciembre del 2016. Ginebra: Organización Mundial de la Salud. 2016. http://www.who.int/tb/areas-of-work/drug-resistant-tb/treatment/FAQshorter_MDR_regimen.pdf.
The use of molecular line probe assays for the detection of resistance to isoniazid and rifampicin. Policy update. WHO/HTM/TB/2016.12. Ginebra: Organización Mundial de la Salud. 2016. http://www.who.int/tb/publications/molecular-test-resistance.
The use of molecular line probe assays for the detection of resistance to second-line anti-TB drugs: policy guidance. WHO/HTM/TB/2016.07. Ginebra: Organización Mundial de la Salud. 2016. http://www.who.int/tb/publications/lpa-mdr-diagnostics.
Considerations for adoption and use of multi-disease testing devices in integrated laboratory networks. WHO/HTM/TB/2017.05. Ginebra: Organización Mundial de la Salud; 2017. https://www.who.int/tb/publications/2017/considerations_multidisease_testing_devices_2017/en/.
Planning for country transition to Xpert® MTB/RIF Ultra cartridges. Ginebra: Global Laboratory Initiative. 2017. http://www.stoptb.org/wg/gli/assets/documents/GLI_ultra.pdf.
WHO meeting report of a technical expert consultation: non-inferiority analysis of Xpert MTB/RIF Ultra compared to Xpert MTB/RIF [WHO/HTM/TB/2017.04]. Ginebra: Organización Mundial de la Salud. 2017. https://www.who.int/tb/publications/2017/XpertUltra/en/.
Line probe assays for drug-resistant TB detection: Interpretation and reporting guide for laboratory staff and clinicians. Ginebra: Global Laboratory Initiative. 2018. http://www.stoptb.org/wg/gli/assets/documents/LPA_test_web_ready.pdf.
Technical manual for drug susceptibility testing of medicines used in the treatment of TB. WHO/CDS/TB/2018.24. Ginebra: Organización Mundial de la Salud. 2018.https://www.who.int/tb/publications/2018/WHO_technical_drug_susceptibility_testing/en/.
WHO treatment guidelines for isoniazid-resistant TB: supplement to the WHO treatment guidelines for drug-resistant TB. WHO/CDS/TB/2018.7. Ginebra: Organización Mundial de la Salud. 2018. http://www.who.int/tb/publications/2018/WHO_guidelines_isoniazid_resistant_TB/en/.
Lateral flow urine lipoarabinomannan assay (LF-LAM) for the diagnosis of active TB in people living with HIV. Policy update 2019. WHO/CDS/TB/2019.16. Ginebra: Organización Mundial de la Salud. 2019. https://www.who.int/tb/publications/2019/LAMPolicyUpdate2019/en/.
Rapid communication: key changes to treatment of multidrug- and rifampicin-resistant TB (MDR/RR-TB). WHO/CDS/TB/2019.26. Ginebra: Organización Mundial de la Salud. 2019. https://www.who.int/tb/publications/2018/rapid_communications_MDR/en/.
WHO consolidated guidelines on drug-resistant TB treatment. WHO/CDS/TB/2019.7. Ginebra: Organización Mundial de la Salud. 2019. https://www.who.int/tb/publications/2019/consolidated-guidelines-drug-resistant-TB-treatment/en/.
Frequently asked questions on the WHO rapid communication 2019: key changes to the treatment of drug-resistant TB. Ginebra: Organización Mundial de la Salud. 2020. https://www.who.int/tb/areas-of-work/drug-resistant-tb/faqs-updated-final-version.pdf?ua=1.
Molecular assays intended as initial tests for the diagnosis of pulmonary and extrapulmonary TB in adults and children. Policy update. Ginebra: Organización Mundial de la Salud; 2020.
4.2 Orientación sobre la implementación de las pruebas diagnósticas
GLI model TB diagnostic algorithms. Ginebra: Global Laboratory initiative. 2017. http://www.stoptb.org/wg/gli/assets/documents/GLI_algorithms.pdf.
GLI practical guide to TB laboratory strengthening. Ginebra: Global Laboratory initiative. 2017. http://www.stoptb.org/wg/gli/gat.asp.
GLI specimen referral toolkit. Ginebra: Global Laboratory Initiative. 2017. http://www.stoptb.org/wg/gli/srt.asp.
4.3 Módulos de capacitación
Training package on culture on solid and liquid medium. Global Laboratory Initiative. 2012. http://www.stoptb.org/wg/gli/assets/documents/Training%20Package%20Culture_October%202012. zip.
Training package on DST by phenotypic and molecular method. Global Laboratory Initiative. 2012. http://www.stoptb.org/wg/gli/assets/documents/Training%20Package%20DST_October%202012 .zip.
Training package on line probe assays (LPAs). Global Laboratory Initiative. 2012. http://www.stoptb.org/wg/gli/assets/documents/Training%20Package%20LPA_%20October%202012. zip.
Training package on Xpert MTB/RIF. Global Laboratory Initiative. 2014. http://www.stoptb.org/wg/gli/TrainingPackage_XPERT_MTB_RIF.asp.
Training package: programme modules for diagnostic network strengthening. Global Laboratory Initiative. 2018. http://www.stoptb.org/wg/gli/TrainingPackage_Programme.asp.